CNS Pharmaceuticals Inc expected to post a loss of $9.60 a share - Earnings Preview

CNS Pharmaceuticals

11/08/2025 13:46

CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to  report resultson August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for CNS Pharmaceuticals Inc is for a loss of $9.60 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "Hold".​

Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $84.00, about 92% above its last closing price of $6.70

This summary was machine generated August 11 at 12:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)